US Edition
ASCO 2025: Ribociclib With NSAI in HR+/HER– Breast Cancer Improves iDFS, Yields Substantial Work Productivity Gains
Summary by Pharmacy Times
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
ASCO 2025: Ribociclib With NSAI in HR+/HER– Breast Cancer Improves iDFS, Yields Substantial Work Productivity Gains
Ribociclib in combination with a nonsteroidal aromatase inhibitor (NSAI) improved invasive disease-free survival (iDFS) while allowing for better quality of life in hormone receptor-positive (HR+)/human epidermal growth receptor 2-negative (HER2−) early breast cancer.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium